Epirubicin

Epirubicin

Clinical data
Pregnancy category	D (Au, U.S.)
Routes of administration	Intravenous
ATC code	L01DB03 (WHO)
Legal status
Legal status	℞-only (U.S.), POM (UK)
Pharmacokinetic data
Bioavailability	NA
Protein binding	77%
Metabolism	Hepatic glucuronidation and oxidation
Excretion	Biliary and renal
Identifiers
IUPAC name 10-(4-amino-5-hydroxy-6-methyl-oxan-2-yl) oxy-6,8,11-trihydroxy-8-(2-hydroxyacetyl)- 1-methoxy-9,10-dihydro-7H-tetracene-5,12-dione
CAS Number	56420-45-2
PubChem CID	41867
DrugBank	APRD00361
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C27H29NO11
Molar mass	543.519 g/mol

WikiDoc Resources for Epirubicin
Articles
Most recent articles on Epirubicin Most cited articles on Epirubicin Review articles on Epirubicin Articles on Epirubicin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Epirubicin Images of Epirubicin Photos of Epirubicin Podcasts & MP3s on Epirubicin Videos on Epirubicin
Evidence Based Medicine
Cochrane Collaboration on Epirubicin Bandolier on Epirubicin TRIP on Epirubicin
Clinical Trials
Ongoing Trials on Epirubicin at Clinical Trials.gov Trial results on Epirubicin Clinical Trials on Epirubicin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Epirubicin NICE Guidance on Epirubicin NHS PRODIGY Guidance FDA on Epirubicin CDC on Epirubicin
Books
Books on Epirubicin
News
Epirubicin in the news Be alerted to news on Epirubicin News trends on Epirubicin
Commentary
Blogs on Epirubicin
Definitions
Definitions of Epirubicin
Patient Resources / Community
Patient resources on Epirubicin Discussion groups on Epirubicin Patient Handouts on Epirubicin Directions to Hospitals Treating Epirubicin Risk calculators and risk factors for Epirubicin
Healthcare Provider Resources
Symptoms of Epirubicin Causes & Risk Factors for Epirubicin Diagnostic studies for Epirubicin Treatment of Epirubicin
Continuing Medical Education (CME)
CME Programs on Epirubicin
International
Epirubicin en Espanol Epirubicin en Francais
Business
Epirubicin in the Marketplace Patents on Epirubicin
Experimental / Informatics
List of terms related to Epirubicin

Overview

Epirubicin is an anthracycline drug used for chemotherapy. It is marketed by Pfizer under the trade name Ellence in the US and Pharmorubicin elsewhere.

Similarly to other anthracyclines, epirubicin acts by intercalating DNA strands. Intercalation results in complex formation which inhibits DNA and RNA synthesis. It also triggers DNA cleavage by topoisomerase II, resulting in mechanisms that lead to cell death. Binding to cell membranes and plasma proteins may be involved in the compound's cytotoxic effects. Epirubicin also generates free radicals that cause cell and DNA damage.

Epirubicin is favoured over doxorubicin, the most popular anthracycline, in some chemotherapy regimens as it appears to cause fewer side-effects. Epirubicin has a different spatial orientation of the hydroxyl group at the 4' carbon of the sugar, which may account for its faster elimination and reduced toxicity. Epirubicin is primarily used against breast and ovarian cancer, gastric cancer, lung cancer, and lymphomas.

Development history

The first trial of epirubicin in humans was published in 1980. Upjohn applied for FDA approval in node-positive breast cancer in 1984, but was turned down because of lack of data. It appears to have been licensed for use in Europe from around this time however. In 1999 Pharmacia (who had by then merged with Upjohn) received FDA approval for the use of epirubicin as a component of adjuvant therapy in node-positive patients.

Patent protection for epirubicin expired in August 2007.

External links

• http://www.bccancer.bc.ca/HPI/DrugDatabase/DrugIndexPro/Epirubicin.htm
• http://www.pfizeroncology.com/products/ellence.aspx